Medical Technologies

2017: VeriLuce license of patents for pancreatic cancer treatment

On July 10, 2017, the NIH issued a notice on "Prospective Grant of Exclusive Patent License: Composition and Methods for Delivering Inhibitory Oligonucleotides for the Treatment of Pancreatic Cancer", to VeriLuce Therapeutics, a very small firm located in Toronto, Ontario, Canada. KEI asked a number of questions about the transaction, and proposed conditions on the license.


July 22, 2017

Novel HIV drug approvals

Names, Date of initial approval, FDA#, Medical Review.

Retrovir, 3/19/1987, FDA#019655, Medical Review
Videx, 10/9/1991, FDA#020154, 020155, 020156, Medical Review
Zerit, 6/24/1994, FDA#020412, Medical Review
Epivir, 11/17/1995, FDA#020564, 020596 , Medical Review
Invirase, 12/6/1995, FDA#020628, Medical Review
Norvir, 3/1/1996, FDA#020659, Medical Review

2017: PathoVax license on Chimeric L1/L2 Protein . .. Human Papillomavirus Vaccines

June 5, 2017

Kevin W. Chang, Ph.D.
Senior Technology Transfer Manager
NCI Technology Transfer Center
9609 Medical Center Drive,
RM 1E530 MSC 9702
Bethesda, MD 20892-9702
Telephone: (240)-276-6910;
Facsimile: (240)-276-5504;

Via Email: changke@mail.nih.gov.

RE: Prospective Grant of Exclusive Patent License: Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines

2017: AbPro license of patents for liver cancer

This was our comment on the license. See below for the June 8, 2017 NIH response, rejecting our requests for changes to the license to address pricing or transparency.


June 2, 2017

David A. Lambertson, Ph.D.,
Senior Licensing and Patenting Manager
NCI Technology Transfer Center
9609 Medical Center Drive
RM 1E530 MSC 9702
Bethesda, MD 20892-9702
Telephone: (240)-276-6467

Via Email: david.lambertson@nih.gov.

2017: GeneXion Oncology Prospective Grant of Exclusive Patent License for Mutant IDH1 Inhibitors

May 31, 2017

Sury Vepa, Ph.D., J.D.,
Senior Licensing and Patenting Manager
National Center for Advancing Translational Sciences'
NIH, 9800 Medical Center Drive, Rockville, MD 20850,
Phone: 301-217-9197,
Fax: 301-217-5736,
email sury.vepa@nih.gov.

RE: Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors

Dear Dr. Vepa,

1. We propose there be language in the license to ensure that prices for products are “reasonable” -- the standard in 35 U.S.C. § 201(f) -- and do not discriminate against U.S. residents.

MedImmune

Founded in 1988.

January 29, 2004. Labs rush to cultivate bird flu vaccine Reverse genetics allows creation of weakened virus , Sabin Russell, Chronicle Medical Writer

Zika

On January 23, 2017, MSF file comments with the US Army in opposition to the grant of an exclusive license to patents on a new vaccine for the Zika Virus. A copy of the filing is on the MSF web page here.

Syndicate content